Cenani Alessia, Brosnan Robert J, Madigan Shara, Knych Heather K, Madigan John E
Veterinary Medical Teaching Hospital, University of California Davis, Davis, CA, USA.
Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California Davis, Davis, CA, USA.
Vet Anaesth Analg. 2017 Jan;44(1):86-97. doi: 10.1111/vaa.12410. Epub 2017 Feb 23.
Propranolol has been suggested for anxiolysis in horses, but its sedation efficacy and side effects, both when administered alone and in combination with α-adrenoceptor agonists, remain undetermined. This study aimed to document the pharmacokinetics and pharmacodynamics of propranolol, romifidine and their combination.
Randomized, crossover study.
Six adult horses weighing 561 ± 48 kg.
Propranolol (1 mg kg; treatment P), romifidine (0.1 mg kg; treatment R) or their combination (treatment PR) were administered intravenously with a minimum of 1 week between treatments. Alertness, behavioral responsiveness (visual and tactile) and physiologic variables were measured before and up to 960 minutes after drug administration. Blood was collected for blood gas and acid-base analyses and measurement of plasma drug concentrations. Data were analyzed using repeated-measures analysis of variance or Friedman with Holm-Sidak and Wilcoxon rank-sum tests (p < 0.05).
Systemic clearance significantly decreased and the area under the concentration-time curve significantly increased for both drugs in PR compared with P and R. Both PR and R decreased behavioral responsiveness and resulted in sedation for up to 240 and 480 minutes, respectively. Sedation was deeper in PR for the first 16 minutes. Heart rate significantly decreased in all treatments for at least 60 minutes, and PR significantly increased the incidence of severe bradycardia (<20 beats minute).
Although not associated with reduced behavioral responsiveness or sedation alone, propranolol augmented romifidine sedation, probably through alterations in romifidine pharmacokinetics, in horses administered PR. The occurrence of severe bradycardia warrants caution in the co-administration of these drugs at the doses studied.
有人提出普萘洛尔可用于马匹的抗焦虑治疗,但其单独使用以及与α - 肾上腺素能受体激动剂联合使用时的镇静效果和副作用仍未确定。本研究旨在记录普萘洛尔、罗米非定及其组合的药代动力学和药效学。
随机交叉研究。
6匹体重为561±48千克的成年马。
静脉注射普萘洛尔(1毫克/千克;治疗组P)、罗米非定(0.1毫克/千克;治疗组R)或它们的组合(治疗组PR),治疗间隔至少1周。在给药前及给药后长达960分钟测量警觉性、行为反应性(视觉和触觉)和生理变量。采集血液进行血气和酸碱分析以及血浆药物浓度测定。使用重复测量方差分析或Friedman检验以及Holm - Sidak和Wilcoxon秩和检验(p<0.05)分析数据。
与治疗组P和R相比,治疗组PR中两种药物的全身清除率显著降低,浓度 - 时间曲线下面积显著增加。治疗组PR和R均降低了行为反应性,分别导致长达240分钟和480分钟的镇静。在最初16分钟内,治疗组PR的镇静作用更深。所有治疗组的心率至少在60分钟内显著降低,治疗组PR显著增加了严重心动过缓(<20次/分钟)的发生率。
虽然普萘洛尔单独使用时与行为反应性降低或镇静无关,但在接受治疗组PR的马匹中,普萘洛尔可能通过改变罗米非定的药代动力学增强了罗米非定的镇静作用。在所研究的剂量下,联合使用这些药物时严重心动过缓的发生需要谨慎。